Compulsory Licensing: Models For State Practice In Developing Countries, Access to Medicine and Compliance with the WTO TRIPS Accord Prepared for the United Nations Development Programme January 21, 2001 James Love Consumer Project on Technology http://www.cptech.org Introduction.1 This note addresses… Continue Reading
2000: Paying for health care R&D – Carrots and Sticks James Love* October 19, 2000 *Thirukumaran Balasubramaniam provided research for this paper. Table of Contents Introduction Failures of the Market Investors cannot appropriate all the benefits of research. R&D is… Continue Reading
How much does it cost to develop a new drug? James Love Consumer Project on Technology http://www.cptech.org April 2, 2000 Prepared for the April 2, 2000 meeting of the MSF Working Group on R&D in Geneva. How much does it… Continue Reading
This statement was developed at the Increasing Access to Essential Drugs in a Globalised Economy Working Towards Solutions conference, which was organized by Health Action International, Médecins Sans Frontières, and Consumer Project on Technology, and took place in Amsterdam, the… Continue Reading
On September 3, 1999, Ralph Nader, James Love and Robert Weisman wrote to Dr. Harold Varmus, then the Director of the NIH, proposing the NIH enter into an agreement with the World Health Organization (WHO), giving the WHO the right… Continue Reading
Ralph Nader P.O. Box 19312, Washington, DC 20036 James Love Consumer Project on Technology P.O. Box 19367, Washington, DC 20036 http://www.cptech.org Robert Weissman Essential Action P.O. Box 19405, Washington, DC 20036 http://www.essentialaction.org/ September 3, 1999 Dr. Harold E. Varmus Building… Continue Reading
Preliminary thoughts on a program for Essential Health Research James Love January 6, 1999 Essential Health Research and the Market In matters concerning public health, intellectual property rights are a means and not an end. Patents and other types of… Continue Reading
CPT has been highly critical of the exclusive marketing provisions in the US and the proposed EU orphan drug acts. Pharmaceutical companies now obtain 20 year patents for inventions, and investments in clinical trials and other research required for drug… Continue Reading
CONFIDENTIAL RELEASED IN FULL CONFIDENTIAL PTQ1906 PAGE 01 GENEVA 03470 01 OF 09 271621Z ACTION 10-00 425261 271705Z /38 O 271615Z MAY 98 FM USMISSION GENEVA TO SECSTATE WASHDC IMMEDIATE 6208 INFO IO COLLECTIVE AMEMBASSY LONDON AMEMBASSY BRASILIA AMEMBASSY BUENOS… Continue Reading
A Free Trade Area For The Americas: A Consumer Perspective On Proposals As They Relate To Rules Regarding Intellectual Property Comments for the Working Group On Intellectual Property Rights, Third Trade Ministerial and Americas Business Forum, Belo Horizonte, Brazil, May… Continue Reading